Synchron is an innovative medical device company focused on the development of minimally invasive neuromodulation technology solutions. Synchron is developing the world's first endovascular neural interface, the StentrodeTM. Development of this technology platform has been funded in part by grants from the U.S. Defense Advanced Research Projects Agency (DARPA) and U.S. Department of Defense (DoD). The company is targeting paralysis due to a range of neurological conditions as a first application.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/04/17 | $10,000,000 | Series A |
Neurotechnology Investors U.S. Department of Defense | undisclosed |
| 06/03/21 | $40,000,000 | Series B |
Arani Bose Forepont Capital Partners General Advance ID8 Investments METIS innovative Neurotechnology Investors re.Mind Capital Shanda Group Subversive Capital Thomas Reardon University of Melbourne | undisclosed |
| 12/15/22 | $75,000,000 | Series C |
Alumni Ventures Group ARCH Venture Partners Bezos Expeditions Forepont Capital Partners Gates Frontier Greenoaks Capital Management ID8 Investments METIS innovative Moore Strategic Ventures Neurotechnology Investors Project X Reliance Digital Health Limited Shanda Group University of Melbourne | undisclosed |
| 11/06/25 | $200,000,000 | Series D |
ARCH Venture Partners Australian National Reconstruction Fund Bezos Expeditions Double Point Ventures IQT K5 Global Khosla Ventures METIS innovative NT Investments Protocol Labs Qatar Investment Authority T.Rx Capital | undisclosed |
